Shanghai Dismisses Researchers Following Fatal Gene Therapy Trial and $900,000 Conflict of Interest
Shanghai authorities dismissed two researchers and sanctioned hospital staff after a fatal gene-editing trial revealed ignored safety warnings and over…

Shanghai authorities have dismissed two senior researchers and sanctioned hospital officials following an investigation into the death of a child during an experimental gene-editing trial. The investigation concluded that the research team and hospital ethics committee failed to adhere to safety protocols, ignored preclinical warning signs, and engaged in undisclosed financial conflicts of interest.
The child, who suffered from Snijders Blok-Campeau syndrome, died in March 2025, seven days after receiving an experimental injection at Hospital. Investigators found that the research team failed to share critical safety data from nonhuman primate trials with the clinical lead, leading to the oversight of significant health risks. Furthermore, the hospital’s ethics committee approved the study despite insufficient toxicology evidence and failed to adequately communicate the risk of death in patient consent forms.
Snijders Blok
Financial irregularities significantly compromised the integrity of the study. The child’s family contributed approximately $800,000 toward the research and provided an additional $160,000 in cash and gifts to the researchers. Specifically, the lead researcher received electronics and liquor, while the primary author of a subsequent paper published in Nature received approximately $136,000 in cash and gifts. Two other team members also received smaller payments. These financial ties were not disclosed in the published research, which also omitted evidence of liver and kidney damage observed in animal trials.
As a result of the findings, the two primary researchers have been dismissed and barred from participating in science and technology programs for five years. They have also been entered into a national database for research integrity violations. The lead investigator of the clinical study and the head of the hospital’s ethics committee were demoted and stripped of administrative responsibilities. Hospital received an undisclosed administrative penalty for its failure to provide independent oversight.
The Shanghai Municipal Health Commission has announced plans to launch special inspections of clinical research involving emerging biomedical technologies. This incident highlights systemic weaknesses in the ethical review process for experimental therapies and underscores the risks associated with financial conflicts in high-stakes medical research. Regulatory bodies are expected to tighten oversight on the approval and monitoring of gene-editing trials to prevent further lapses in patient safety.
More stories
- Dietitians advise small swaps for plant-based eating
- TikTok dementia videos mislead in 66.4% of sample, researchers say
- Aberdeen Royal Infirmary faces police inquiry call over 19 deaths
- Bariatric surgery group loses 28.2% after GLP-1 use
- TOFA boosts mouse energy use 18% while preserving muscle
- ICO probes NHS therapy notes accessible to up to 140,000 staff
- Higher arginine diets were associated with fewer colon tumors in mice
- Singapore CDA gains first WHO infection-control centre role
- Noom, tailored meals slow regain after GLP-1s in trial
- GLP-1 users report nail detachment at 39% in survey
Latest news
- David Parr House to honor Victorian art-workman with blue plaque
- Iran's attacks hit 25 tankers near Strait of Hormuz
- FCC approves prison cellphone jamming despite 2.5-mile warning
- Russia strikes Ukraine as Odesa faces electricity strain
- Bahrain reports two injuries after Iranian aerial attacks
- Congress tests Black Democrats' growing policy influence
- Baltic responders fight Sparta II fire after drone strike
- Europe faces attribution gap after 16 cyber, physical incidents

